EUVIMEDEUVIMED entdecken
Crossref

Downstaging as a direct patient benefit in cancer screening

Paul F Pinsky iD, Elyse M LeeVan, Wendy S Rubinstein, Christos Patriotis, Lori Minasian

Journal of Medical Screening · 2026-12 · 33 (4) · 264-271

DOI: 10.1177/09691413261473145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Screening, online erschienen am 31.07.2026. Verfasst von Paul F Pinsky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Early Detection of Cancer, Lung Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The standard metric to assess the benefit of cancer screening is reduction in cancer-specific mortality. However, patients may benefit from downstaging of disease due to screening, even among those who would have survived late-stage disease absent screening.

Methods

We developed a model of stage and survival in the absence and presence of screening. Within each stage/survival category without screening, there are transition probabilities to various stage/survival and mode of detection (screen detected or not) categories under screening. The model includes rules for allowable transitions; for example, stage and survival are unchanged for non-screen detected cancers, and survival status changing from dying to surviving requires downstaging. A two-stage (early/late) model was fit to National Lung Screening Trial (NLST) data. The low-dose computed tomography (LDCT) arm was considered the screening arm and the chest radiograph arm the control (non-screening) arm.

Results

There were 1032 and 993 lung cancer cases in the NLST LDCT and control arm, respectively. 15.2% of control arm cases were late-stage (III/IV) survivors. Their rate of transitioning to early-stage (I/II) survivors under screening was 18.4%, resulting in 2.8% (15.2% * 18.4%) of all cases transitioning from late-stage survivors under no screening to early-stage survivors with screening. 47.1% of late-stage control arm cases did not survive; their rate of transitioning to early-stage survivors under screening was 21.5%, resulting in 10.1% (47.1% * 21.5%) of all cases under no screening with that transition.

Conclusions

Modeling the effects of screening on stage and survival can help elucidate a more holistic set of screening benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerLung NeoplasmsHumansNeoplasm StagingTomography, X-Ray ComputedFemaleMaleMiddle AgedAgedMass Screening

Stichwörter der Autor:innen

Screeningdownstaginglung cancermodeling

Autor:innen und Institutionen

  • Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Paul F Pinsky

Zitieren

APA

Pinsky, P. F., LeeVan, E. M., Rubinstein, W. S., Patriotis, C., & Minasian, L. (2026). Downstaging as a direct patient benefit in cancer screening. Journal of Medical Screening, 33(4), 264-271. https://doi.org/10.1177/09691413261473145

Vancouver

Pinsky PF, LeeVan EM, Rubinstein WS, Patriotis C, Minasian L. Downstaging as a direct patient benefit in cancer screening. Journal of Medical Screening. 2026;33(4):264-271. doi:10.1177/09691413261473145

BibTeX
@article{Pinsky2026,
  author = {Pinsky, Paul F and LeeVan, Elyse M and Rubinstein, Wendy S and Patriotis, Christos and Minasian, Lori},
  title = {Downstaging as a direct patient benefit in cancer screening},
  journal = {Journal of Medical Screening},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {264--271},
  doi = {10.1177/09691413261473145}
}
Kostenlos starten →